EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival

Alison Roos, Harshil D. Dhruv, Sen Peng, Landon J. Inge, Serdar Tuncali, Michael Pineda, Nghia Millard, Zachary Mayo, Jennifer M. Eschbacher, Joseph C Loftus, Jeffrey A. Winkles, Nhan Tran

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival.

Original languageEnglish (US)
Pages (from-to)1185-1195
Number of pages11
JournalMolecular Cancer Research
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Glioblastoma
Cell Movement
Cell Survival
Neoplasms
Pimozide
Therapeutics
Glioma
Phosphorylation
epidermal growth factor receptor VIII
Phenotype
Recurrence
Survival
Brain

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival. / Roos, Alison; Dhruv, Harshil D.; Peng, Sen; Inge, Landon J.; Tuncali, Serdar; Pineda, Michael; Millard, Nghia; Mayo, Zachary; Eschbacher, Jennifer M.; Loftus, Joseph C; Winkles, Jeffrey A.; Tran, Nhan.

In: Molecular Cancer Research, Vol. 16, No. 7, 01.07.2018, p. 1185-1195.

Research output: Contribution to journalArticle

Roos, A, Dhruv, HD, Peng, S, Inge, LJ, Tuncali, S, Pineda, M, Millard, N, Mayo, Z, Eschbacher, JM, Loftus, JC, Winkles, JA & Tran, N 2018, 'EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival', Molecular Cancer Research, vol. 16, no. 7, pp. 1185-1195. https://doi.org/10.1158/1541-7786.MCR-18-0125
Roos, Alison ; Dhruv, Harshil D. ; Peng, Sen ; Inge, Landon J. ; Tuncali, Serdar ; Pineda, Michael ; Millard, Nghia ; Mayo, Zachary ; Eschbacher, Jennifer M. ; Loftus, Joseph C ; Winkles, Jeffrey A. ; Tran, Nhan. / EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival. In: Molecular Cancer Research. 2018 ; Vol. 16, No. 7. pp. 1185-1195.
@article{52db9443be9a4e8e9b8a6e0a9dfb2c13,
title = "EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival",
abstract = "Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50{\%} of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival.",
author = "Alison Roos and Dhruv, {Harshil D.} and Sen Peng and Inge, {Landon J.} and Serdar Tuncali and Michael Pineda and Nghia Millard and Zachary Mayo and Eschbacher, {Jennifer M.} and Loftus, {Joseph C} and Winkles, {Jeffrey A.} and Nhan Tran",
year = "2018",
month = "7",
day = "1",
doi = "10.1158/1541-7786.MCR-18-0125",
language = "English (US)",
volume = "16",
pages = "1185--1195",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival

AU - Roos, Alison

AU - Dhruv, Harshil D.

AU - Peng, Sen

AU - Inge, Landon J.

AU - Tuncali, Serdar

AU - Pineda, Michael

AU - Millard, Nghia

AU - Mayo, Zachary

AU - Eschbacher, Jennifer M.

AU - Loftus, Joseph C

AU - Winkles, Jeffrey A.

AU - Tran, Nhan

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival.

AB - Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival.

UR - http://www.scopus.com/inward/record.url?scp=85049314597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049314597&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-18-0125

DO - 10.1158/1541-7786.MCR-18-0125

M3 - Article

C2 - 29724813

AN - SCOPUS:85049314597

VL - 16

SP - 1185

EP - 1195

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 7

ER -